RESUMEN
In the process of the drug development, studies on the cytochrome P450 (CYP) profiles after its administration provided fundamental information regarding drug interactions with concomitantly administered drugs. Here, we evaluated the influence of the administration of H12-(ADP)-liposomes, a platelet substitute, on the mRNA and protein expression, and metabolic activity of CYPs, with focus on the CYP1A2, CYP2C11 and CYP3A2, in rat liver.At 24 h after administering saline or H12-(ADP)-liposomes (10 mg of lipids/kg), a quantitative RT-PCR and western blot analysis revealed that the mRNA and proteins expression of all of the target hepatic CYP isoforms were not different between the saline and H12-(ADP)-liposome groups. Furthermore, an ex vivo CYP metabolic activity assay showed that hepatic CYP metabolic activities in the H12-(ADP)-liposome group were comparable to the corresponding saline group. On the other hand, the area under the blood concentration-time curve for substitutes for CYP1A2 and CYP2C11 was higher in H12-(ADP)-liposome group than in saline group, but the degree of elevations was negligible levels.At a minimum, based on these results, we conclude that H12-(ADP)-liposomes have no quantitative and qualitative effect on the hepatic CYP isoforms, indicating that the drug interactions of H12-(ADP)-liposomes with CYP-metabolizing drugs would be negligible.
RESUMEN
It was recently reported that the dexmedetomidine concentration within the extracorporeal circuit decreases with co-administration of midazolam. In this study, we investigated whether displacement of dexmedetomidine by midazolam from the binding site of major plasma proteins, human serum albumin (HSA) and α1-acid glycoprotein (AAG), would increase levels of free dexmedetomidine that could be adsorbed to the circuit. Equilibrium dialysis experiments indicated that dexmedetomidine binds to a single site on both HSA and AAG with four times greater affinity than midazolam. Midazolam-mediated inhibition of the binding of dexmedetomidine to HSA and AAG was also examined. The binding of dexmedetomidine to these proteins decreased in the presence of midazolam. Competitive binding experiments suggested that the inhibition of binding by midazolam was due to competitive displacement at site II of HSA and due to non-competitive displacement at the site of AAG. Thus, our present data indicate that free dexmedetomidine displaced by midazolam from site II of HSA or from AAG is adsorbed onto extracorporeal circuits, resulting in a change in the dexmedetomidine concentration within the circuit.
Asunto(s)
Dexmedetomidina , Midazolam , Humanos , Unión Proteica/fisiología , Dexmedetomidina/farmacología , Proteínas Sanguíneas/metabolismo , Orosomucoide/metabolismo , Albúmina Sérica Humana/metabolismoRESUMEN
Red cell transfusions, which deteriorate in quality during storage, triggers several negative biological responses. However, little is known regarding the effects of stored red cell transfusion on cytochrome P450 (P450) profiles. To clarify this issue, we investigated hepatic P450 profiles in hemorrhagic shock model rats after resuscitation with stored packed red cells (PRC). The pharmacokinetics data for P450-metabolizing substrates showed that the clearance of substrates for Cyp1A2 and Cyp3A2 in the stored PRC resuscitation group were decreased compared to sham group. The protein expression, metabolic activity and mRNA expression of the P450 isoforms in the stored PRC resuscitation group were lower than the corresponding values for the sham group. However, these changes would be expected to have weak effects on the in vivo pharmacokinetics of the concomitant drugs based on the criteria stated in the guideline on drug interactions. In contrast, the results of these P450 profiles in the stored PRC and fresh PRC resuscitation group exhibited a similar trend. These results suggest that the stored PRC transfusion has an influence on the hepatic P450 profiles, but is of little clinical significance, not by the deterioration of the quality of red cells but pathophysiological alterations following the hemorrhage and transfusion.
Asunto(s)
Preparaciones Farmacéuticas , Choque Hemorrágico , Animales , Sistema Enzimático del Citocromo P-450/genética , Eritrocitos , Hígado , Ratas , Ratas Sprague-Dawley , Choque Hemorrágico/terapiaRESUMEN
Hemoglobin-vesicles (Hb-V) are being developed as red blood cell (RBC) substitutes. In this study, we report on quantitative and qualitative alterations of hepatic cytochrome P450 (CYPs) and the pharmacokinetics of CYP-metabolizing drugs, with a focus on four CYP isoforms (CYP1A2, CYP2C11, CYP2E1 and CYP3A2), after Hb-V resuscitation from a massive hemorrhage. The results of proteome analysis and western blot data indicate that resuscitation with both Hb-V and packed RBC (PRBC) resulted in a decrease in the protein levels of CYPs. Along with a decrease in the protein expression of CYPs, pharmacokinetic studies showed that the elimination of CYP-metabolizing drugs was prolonged in the Hb-V and PRBC resuscitation groups. It is also noteworthy that the CYP-metabolizing drugs in the Hb-V resuscitation group was retained for a longer period compared to the PRBC resuscitation group, and this is attributed to the CYP isoforms having a lower metabolic activity in the Hb-V resuscitation group than that for the PRBC resuscitation group. These findings suggest that resuscitation with Hb-V after a massive hemorrhage has a slight but not clinically significant effect on drug metabolism via CYPs in the liver due to decreased protein levels and the metabolic activity with respect to the CYPs.
Asunto(s)
Cafeína/metabolismo , Clorzoxazona/metabolismo , Sistema Enzimático del Citocromo P-450/metabolismo , Hemoglobinas/metabolismo , Midazolam/metabolismo , Choque Hemorrágico/metabolismo , Tolbutamida/metabolismo , Animales , Cafeína/química , Clorzoxazona/química , Sistema Enzimático del Citocromo P-450/química , Interacciones Farmacológicas , Hemoglobinas/química , Liposomas/química , Liposomas/metabolismo , Masculino , Midazolam/química , Ratas , Ratas Sprague-Dawley , Tolbutamida/químicaRESUMEN
Hemoglobin-vesicles (Hb-V), hemoglobin encapsulated within a liposome, were developed as an artificial red blood cell (RBC). When Hb-V becomes clinically available in the future, patients would presumably be co-administered with one or more drugs. Since drug-drug interactions can cause serious adverse effects and impede overall curative effects, evidence regarding the risk associated with drug-drug interactions between Hb-V and such simultaneously administered drugs is needed. Therefore, we report on cytochrome P450 (CYP)-based drug interactions with Hb-V in healthy rats. At 1 day after the saline, Hb-V or packed RBC (PRBC) administration, the blood retention of CYP-metabolizing drugs (caffeine, chlorzoxazone, tolbutamide and midazolam) were moderately prolonged in the case of the Hb-V group, but not the PRBC group, compared to saline group. The results of a proteome analysis revealed that the Hb-V administration had only negligible effects on the protein expression of CYPs in the liver. Hb-V administration, however, clearly suppressed the CYP metabolic activity of the four target CYP isoforms compared with the saline and PRBC group. However, these alterations were nearly recovered at 7 day after the Hb-V administration. Taken together, these results suggest that the administration of Hb-V slightly and transiently affects the CYP-based metabolism of the above drugs.
Asunto(s)
Cafeína/farmacocinética , Clorzoxazona/farmacocinética , Sistema Enzimático del Citocromo P-450/metabolismo , Hemoglobinas/metabolismo , Midazolam/farmacocinética , Tolbutamida/farmacocinética , Animales , Cafeína/química , Clorzoxazona/química , Sistema Enzimático del Citocromo P-450/química , Interacciones Farmacológicas , Hemoglobinas/química , Liposomas/química , Liposomas/metabolismo , Masculino , Midazolam/química , Ratas , Ratas Sprague-Dawley , Tolbutamida/químicaRESUMEN
Hemoglobin-vesicles (HbV), encapsulating highly concentrated human hemoglobin in liposomes, were developed as a substitute for red blood cells (RBC) and their safety and efficacy in transfusion therapy has been confirmed in previous studies. Although HbV suspensions are structurally and physicochemically stabile for least 1-year at room temperature, based on in vitro experiments, the issue of whether the use of long-term stored HbV after a massive hemorrhage can be effective in resuscitations without adverse, post-transfusion effects remains to be clarified. We report herein on a comparison of the systemic response and the induction of organ injuries in hemorrhagic shock model rats resuscitated using 1-year-stored HbV, freshly packed RBC (PRBC-0) and by 28-day-stored packed RBC (PRBC-28). The six-hour mortality after resuscitation was not significantly different among the groups. Arterial blood pressure and blood gas parameters revealed that, using HbV, recovery from the shock state was comparable to that when PRBC-0 was used. Although no significant change was observed in serum parameters reflecting liver and kidney injuries at 6 hours after resuscitation among the three resuscitation groups, results based on Evans Blue and protein leakage in bronchoalveolar lavage fluid, the lung wet/dry weight ratio and histopathological findings indicated that HbV as well as PRBC-0 was less predisposed to result in a post-transfusion lung injury than PRBC-28, as evidenced by low levels of myeloperoxidase accumulation and subsequent oxidative damage in the lung. The findings reported herein indicate that 1-year-stored HbV can effectively function as a resuscitative fluid without the induction of post-transfused lung injury and that it is comparable to fresh PRBC, suggesting that HbV is a promising RBC substitute with a long shelf-life.
Asunto(s)
Lesión Pulmonar Aguda/etiología , Transfusión de Eritrocitos , Eritrocitos/metabolismo , Hemoglobinas/administración & dosificación , Hemorragia/sangre , Hemorragia/complicaciones , Liposomas , Resucitación , Lesión Renal Aguda/etiología , Lesión Renal Aguda/metabolismo , Lesión Pulmonar Aguda/patología , Animales , Análisis de los Gases de la Sangre , Glucemia , Citocinas/metabolismo , Modelos Animales de Enfermedad , Hematócrito , Hemorragia/etiología , Hemorragia/terapia , Insuficiencia Hepática/etiología , Insuficiencia Hepática/metabolismo , Mediadores de Inflamación/metabolismo , Pruebas de Función Renal , Pruebas de Función Hepática , Masculino , Estrés Oxidativo , Oxígeno/metabolismo , Ratas , Pruebas de Función Respiratoria , Choque Hemorrágico/sangre , Choque Hemorrágico/complicaciones , Choque Hemorrágico/etiología , Choque Hemorrágico/terapia , Tasa de Supervivencia , Resultado del TratamientoRESUMEN
Hemerocallis fulva L. var. sempervirens M. Hotta (kwanso) represents an exceptional resource for identifying and developing new phytomedicines for the treatment and prevention of disease. The aim of this study was to conduct a detailed investigation of the biological activities of kwanso. Our study resulted in four major findings. First, kwanso scavenges hydroxyl radicals generated by H(2)O(2)/UV light system in vitro in a dose-dependent manner. Second, hepatic glutathione levels were significantly increased when kwanso was orally administered to mice. Third, the oral administration of kwanso to mice showed a tendency to suppress hepatic injury induced by acetaminophen. Finally, kwanso slightly inhibited cytochrome P450 3A activity. These results provide useful evidence in support of the development of kwanso as a candidate raw material for the treatment and prevention of disease.